Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks
-
By
-
Howard L. Sofen
-
Ranga Gogineni
-
Tushar Nishandar
-
Jerry Bagel
-
May 9, 2026